Jupiter Neurosciences (JUNS) Cash & Equivalents (2023 - 2025)
Jupiter Neurosciences (JUNS) posted quarterly Cash & Equivalents of $723797.0 for Q3 2025, up 285985.77% year-over-year from N/an in Q3 2024, and down 61.46% quarter-over-quarter from $1.9 million in Q2 2025.
Jupiter Neurosciences (JUNS) Cash & Equivalents (2023 - 2025) Analysis & Trends
Jupiter Neurosciences (JUNS) has reported Cash & Equivalents for 3 consecutive years, with $723797.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Cash & Equivalents rose 285985.77% year-over-year to $723797.0; the TTM figure through Sep 2025 stood at $723797.0 (up 285985.77% YoY), while the FY2024 annual figure was $3.8 million, up 13136.57% from the prior year.
- Cash & Equivalents fell to $723797.0 in Q3 2025 per JUNS's latest filing, from $1.9 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $3.8 million in Q4 2024 and bottomed at $253.0 in Q3 2024.
- Historically, Cash & Equivalents has averaged $1.0 million across 3 years, with a median of $59615.0 in 2023.
- Annual changes were most pronounced in 2024 — Cash & Equivalents tumbled 99.58% — and 2025, when it jumped 285985.77%.
- Jupiter Neurosciences' Cash & Equivalents stood at $28478.0 in 2023, then soared by 13136.57% to $3.8 million in 2024, then tumbled by 80.8% to $723797.0 in 2025.
- Business Quant data shows JUNS's Cash & Equivalents at $723797.0 in Q3 2025, $1.9 million in Q2 2025, and $2.7 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Jupiter Neurosciences | 3.37 Mn | 1.85 Mn | 21,064.00 | 1.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 723,797.00 |
| Jun 30, 2025 | 1.88 Mn |
| Mar 31, 2025 | 2.71 Mn |
| Dec 31, 2024 | 3.77 Mn |
| Sep 30, 2024 | 253.00 |
| Jun 30, 2024 | 14,851.00 |
| Mar 31, 2024 | 8,313.00 |
| Dec 31, 2023 | 28,478.00 |
| Sep 30, 2023 | 59,615.00 |